GynQura Therapeutics
The project will harness the development of a biobank of patient-derived organoids into an endometriosis drug discovery platform, to identify targets and develop first-in-class, non-hormonal therapeutics, that directly impact the endometriotic ectopic lesions.
Project summary
Purpose
Harnessing patient-derived organoids into drug discovery toward the development of first-in-class targeted therapeutics for endometriosis
Host university
KU Leuven
Funding per year
DKK 6,5M
Duration
Three years
Expected outcome
Viable startup that can raise seed or Series A financing
Project leaders
See who heads GynQura Therapeutics on its mission to develop first-in-class targeted therapeutics for endometriosis.
“GynQura has established a unique biobank of patient-derived organoids from women with endometriosis, which enables a novel approach to identifying better treatment options for the affected women.”
Maj Hedtjärn
Entrepreneur in Residence